Logo image of IBAC

IB ACQUISITION CORP (IBAC) Stock Fundamental Analysis

USA - NASDAQ:IBAC - US44934N1081 - Common Stock

10.5 USD
+0.03 (+0.29%)
Last: 10/3/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, IBAC scores 2 out of 10 in our fundamental rating. IBAC was compared to 0 industry peers in the Unkown industry. The financial health of IBAC is average, but there are quite some concerns on its profitability. IBAC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IBAC was profitable.
In the past year IBAC has reported a negative cash flow from operations.
IBAC Yearly Net Income VS EBIT VS OCF VS FCFIBAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 500K -500K 1M 1.5M

1.2 Ratios

Industry RankSector Rank
ROA 2.94%
ROE 2.95%
ROIC N/A
ROA(3y)-10.93%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBAC Yearly ROA, ROE, ROICIBAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 50 100

1.3 Margins

IBAC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBAC Yearly Profit, Operating, Gross MarginsIBAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for IBAC has been increased compared to 1 year ago.
There is no outstanding debt for IBAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IBAC Yearly Shares OutstandingIBAC Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
IBAC Yearly Total Debt VS Total AssetsIBAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 65.86 indicates that IBAC is not in any danger for bankruptcy at the moment.
There is no outstanding debt for IBAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 65.86
ROIC/WACCN/A
WACCN/A
IBAC Yearly LT Debt VS Equity VS FCFIBAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

IBAC has a Current Ratio of 1.14. This is a normal value and indicates that IBAC is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.14 indicates that IBAC should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.14
IBAC Yearly Current Assets VS Current LiabilitesIBAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200K 400K 600K 800K 1M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38940.00% over the past year.
EPS 1Y (TTM)38940%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 45.65, which means the current valuation is very expensive for IBAC.
IBAC is valuated expensively when we compare the Price/Earnings ratio to 27.86, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 45.65
Fwd PE N/A
IBAC Price Earnings VS Forward Price EarningsIBAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBAC Per share dataIBAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IBAC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IB ACQUISITION CORP

NASDAQ:IBAC (10/3/2025, 8:00:02 PM)

10.5

+0.03 (+0.29%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)08-12 2025-08-12
Earnings (Next)12-24 2025-12-24
Inst Owners79.04%
Inst Owner Change0%
Ins Owners6.45%
Ins Owner Change0%
Market Cap60.27M
AnalystsN/A
Price TargetN/A
Short Float %0%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 45.65
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.5
EV/EBITDA N/A
EPS(TTM)0.23
EY2.19%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS21.19
TBVpS21.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.94%
ROE 2.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.93%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1.14
Altman-Z 65.86
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38940%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.45%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7605.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-410400%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-410400%
OCF growth 3YN/A
OCF growth 5YN/A